{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T04:25:53Z","timestamp":1792211153039,"version":"4.4.0"},"reference-count":220,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T00:00:00Z","timestamp":1681257600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Reports"],"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Squamous cell carcinoma (SCC) is a relatively common and heterogenous malignancy of different organs, such as the skin, esophagus, and lungs. Although most cases experience good survival with surgical methods, management of advanced types of the disease remains challenging. Several modalities, including different chemotherapy regimens and immunotherapies, have been investigated in this matter, among which Monoclonal antibodies (Mabs) are one of the most promising ones. Since the development of Mabs, they have been widely used to treat different diseases. Mabs have shown significant efficacy with high specificity along with acceptable safety, which makes them a favorable option in cancer therapy. In this article, we aimed to review the different aspects of using Mabs in SCC therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Recent Findings<\/jats:title><jats:p>We found that treating with different Mabs has shown excellent efficacy accompanied by acceptable safety in treating SCC of different organs. Therefore, Mabs are considered great options in the treatment of SCC, especially in advanced cases. Overall, two highly potent types of Mabs in SCC therapy are anti\u2010EGFR Mabs and checkpoint inhibitors, especially Cetuximab, Nimotuzumab, and PD\u20101 inhibitors. Bevacizumab is also a promising option as adjuvant therapy to other modalities.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Although some Mabs have shown promising outcomes in SCC therapy, their application as a part of cancer treatment depends on further investigations regarding cost\u2010effectiveness and predictors of response. FDA has approved several Mabs in SCC therapies, and Mabs may have a crucial role in this era in the near future, especially in treating head and neck and esophageal SCC and metastatic lung cancer.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cnr2.1802","type":"journal-article","created":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T09:14:40Z","timestamp":1681290880000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Monoclonal antibodies for the treatment of squamous cell carcinoma: A literature review"],"prefix":"10.1002","volume":"6","author":[{"given":"Amirhossein","family":"Tamimi","sequence":"first","affiliation":[{"name":"Student Research Committee, School of Medicine Guilan University of Medical Sciences  Rasht Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atena","family":"Tamimi","sequence":"additional","affiliation":[{"name":"Student Research Committee, School of Medicine Shahid Beheshti University of Medical Sciences  Tehran Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8130-6471","authenticated-orcid":false,"given":"Fatemeh","family":"Sorkheh","sequence":"additional","affiliation":[{"name":"Student Research Committee Babol University of Medical Sciences  Babol Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saba Mardekatani","family":"Asl","sequence":"additional","affiliation":[{"name":"Student Research Committee, School of Medicine Shahid Beheshti University of Medical Sciences  Tehran Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arezoo","family":"Ghafari","sequence":"additional","affiliation":[{"name":"Student Research Committee, School of Medicine Shahid Beheshti University of Medical Sciences  Tehran Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arian Ghannadi","family":"Karimi","sequence":"additional","affiliation":[{"name":"Student Research Committee Qazvin University of Medical Science  Qazvin Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gisou","family":"Erabi","sequence":"additional","affiliation":[{"name":"Student Research Committee Urmia University of Medical Sciences  Urmia Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9629-2284","authenticated-orcid":false,"given":"Hossein","family":"Pourmontaseri","sequence":"additional","affiliation":[{"name":"Student Research Committee Fasa University of Medical Sciences  Fasa Iran"},{"name":"Bitab knowledge Enterprise Fasa University of Medical Sciences  Fasa Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niloofar","family":"Deravi","sequence":"additional","affiliation":[{"name":"Student Research Committee, School of Medicine Shahid Beheshti University of Medical Sciences  Tehran Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,4,12]]},"reference":[{"key":"e_1_2_13_2_1","unstructured":"Squamous Cell Carcinoma \u2010 Patient Information.2018http:\/\/skincancer.dermis.net\/content\/e04typesof\/e151\/e152\/index_eng.html"},{"key":"e_1_2_13_3_1","unstructured":"UK CR.Non\u2010melanoma skin cancer risk factors.2018https:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/non-melanoma-skin-cancer\/risk-factors?_ga=2.24286266.105500268.1603401442-203461390.1603401442#heading-One"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.1590\/abd1806-4841.20153465"},{"key":"e_1_2_13_5_1","volume-title":"Robbins Basic Pathology e\u2010book","author":"Kumar V","year":"2017"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/odi.13525"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-009-0023-5"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jare.2021.06.014"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2013.2139"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/ctg.2016.64"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.3390\/nu11081903"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.56.2736"},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.06.411"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2013.09.009"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.40.3774"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2241"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.3390\/antib9030034"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd1381"},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.04.001"},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10456-004-8272-2"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.1101\/gad.314617.118"},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.1186\/s43141-021-00264-6"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11033-018-4427-x"},{"key":"e_1_2_13_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2013.02.009"},{"key":"e_1_2_13_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3365"},{"key":"e_1_2_13_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa052306"},{"key":"e_1_2_13_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/nbt1137"},{"key":"e_1_2_13_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2403"},{"key":"e_1_2_13_29_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0500014102"},{"key":"e_1_2_13_30_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pharmtox-010510-100510"},{"key":"e_1_2_13_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd1386"},{"key":"e_1_2_13_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3003"},{"key":"e_1_2_13_33_1","first-page":"1","article-title":"Monoclonal antibodies in human cancer","volume":"39","author":"Mellstedt H","year":"2003","journal-title":"Drugs Today"},{"key":"e_1_2_13_34_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0802656"},{"key":"e_1_2_13_35_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.06.7447"},{"key":"e_1_2_13_36_1","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.22189"},{"key":"e_1_2_13_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20477"},{"key":"e_1_2_13_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00005-012-0189-7"},{"key":"e_1_2_13_39_1","doi-asserted-by":"publisher","DOI":"10.1080\/01480545.2016.1209678"},{"key":"e_1_2_13_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2005.10.018"},{"key":"e_1_2_13_41_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00849"},{"issue":"2","key":"e_1_2_13_42_1","first-page":"2182","article-title":"Apoptosis\u2010inducing effects of cetuximab combined with radiotherapy and hypothermia on human nasopharyngeal carcinoma CNE cells","volume":"8","author":"Liu W","year":"2015","journal-title":"Int J Clin Exp Med"},{"issue":"2","key":"e_1_2_13_43_1","first-page":"257","article-title":"Anti\u2010epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice","volume":"5","author":"Perrotte P","year":"1999","journal-title":"Clin Cancer Res"},{"key":"e_1_2_13_44_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.01.504"},{"key":"e_1_2_13_45_1","doi-asserted-by":"publisher","DOI":"10.1186\/1748-717X-1-11"},{"key":"e_1_2_13_46_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa053422"},{"key":"e_1_2_13_47_1","first-page":"173","article-title":"The contribution of cetuximab in the treatment of recurrent and\/or metastatic head and neck cancer","volume":"4","author":"Tejani MA","year":"2010","journal-title":"Biol: Targets Ther"},{"key":"e_1_2_13_48_1","doi-asserted-by":"publisher","DOI":"10.4103\/0019-509X.82872"},{"key":"e_1_2_13_49_1","doi-asserted-by":"publisher","DOI":"10.3109\/09546634.2012.751481"},{"key":"e_1_2_13_50_1","doi-asserted-by":"publisher","DOI":"10.1002\/hed.26053"},{"key":"e_1_2_13_51_1","doi-asserted-by":"publisher","DOI":"10.21873\/invivo.12084"},{"key":"e_1_2_13_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00136-4"},{"key":"e_1_2_13_53_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002996"},{"key":"e_1_2_13_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70034-1"},{"key":"e_1_2_13_55_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-014-2459-z"},{"key":"e_1_2_13_56_1","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.2012.643864"},{"key":"e_1_2_13_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70181-5"},{"key":"e_1_2_13_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)71198-2"},{"key":"e_1_2_13_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)71200-8"},{"key":"e_1_2_13_60_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11307-013-0652-9"},{"key":"e_1_2_13_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2015.08.001"},{"key":"e_1_2_13_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2013.11.008"},{"key":"e_1_2_13_63_1","doi-asserted-by":"publisher","DOI":"10.4161\/cbt.9.5.10981"},{"key":"e_1_2_13_64_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-013-0564-3"},{"key":"e_1_2_13_65_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.8225"},{"key":"e_1_2_13_66_1","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.12789"},{"key":"e_1_2_13_67_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-017-0631-7"},{"key":"e_1_2_13_68_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-022-02602-5"},{"key":"e_1_2_13_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00021-2"},{"key":"e_1_2_13_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)70046-X"},{"key":"e_1_2_13_71_1","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.13999"},{"key":"e_1_2_13_72_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-011-9850-y"},{"key":"e_1_2_13_73_1","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2018-0093"},{"key":"e_1_2_13_74_1","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/852748"},{"issue":"1","key":"e_1_2_13_75_1","first-page":"49","article-title":"Concurrent biological targeting therapy of squamous cell carcinoma of the esophagus with cetuximab and trastuzumab","volume":"28","author":"Yamazaki M","year":"2012","journal-title":"Oncol Rep"},{"key":"e_1_2_13_76_1","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-10-42"},{"key":"e_1_2_13_77_1","doi-asserted-by":"publisher","DOI":"10.5732\/cjc.012.10263"},{"key":"e_1_2_13_78_1","doi-asserted-by":"publisher","DOI":"10.5603\/GP.2016.0052"},{"key":"e_1_2_13_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2018.05.014"},{"key":"e_1_2_13_80_1","doi-asserted-by":"publisher","DOI":"10.2174\/157436211795659955"},{"key":"e_1_2_13_81_1","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.00152"},{"key":"e_1_2_13_82_1","doi-asserted-by":"publisher","DOI":"10.1093\/toxsci\/kfy141"},{"key":"e_1_2_13_83_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2016.05.011"},{"key":"e_1_2_13_84_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoto.2015.2381"},{"key":"e_1_2_13_85_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12061537"},{"key":"e_1_2_13_86_1","first-page":"92","article-title":"302 antitumor activity of ficlatuzumab in combination with cetuximab on squamous cell carcinomas of the head and neck","volume":"48","author":"Meetze K","year":"2012","journal-title":"Eur J Cancer"},{"key":"e_1_2_13_87_1","doi-asserted-by":"publisher","DOI":"10.1186\/1756-9966-29-83"},{"key":"e_1_2_13_88_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.18.9043"},{"key":"e_1_2_13_89_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa032691"},{"key":"e_1_2_13_90_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa021491"},{"key":"e_1_2_13_91_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.4645"},{"key":"e_1_2_13_92_1","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0b013e3182329791"},{"issue":"2","key":"e_1_2_13_93_1","first-page":"136","article-title":"Bevacizumab inhibits angiogenic cytokines in head and neck squamous cell carcinoma: from gene to the protein","volume":"12","author":"Heydar H","year":"2018","journal-title":"Int J Hematol\u2010Oncol Stem Cell Research"},{"key":"e_1_2_13_94_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.27498"},{"key":"e_1_2_13_95_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.33.3591"},{"issue":"5","key":"e_1_2_13_96_1","first-page":"942","article-title":"Phase 1 trial of bevacizumab with concurrent chemoradiation therapy for squamous cell carcinoma of the head and neck with exploratory functional imaging of tumor hypoxia, proliferation, and perfusion. International Journal of Radiation Oncology* Biology*","volume":"91","author":"Nyflot MJ","year":"2015","journal-title":"Physics"},{"issue":"6","key":"e_1_2_13_97_1","first-page":"645","article-title":"Targeted therapeutic approaches in vulvar squamous cell cancer (VSCC): case series and review of the literature","volume":"28","author":"Woelber L","year":"2020","journal-title":"Oncol Res Featur Preclin Clin Cancer Ther"},{"key":"e_1_2_13_98_1","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-9-126"},{"key":"e_1_2_13_99_1","doi-asserted-by":"publisher","DOI":"10.1089\/cbr.2017.2216"},{"key":"e_1_2_13_100_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2016.00232"},{"key":"e_1_2_13_101_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2019.12.020"},{"key":"e_1_2_13_102_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.26427"},{"key":"e_1_2_13_103_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-011-1713-x"},{"key":"e_1_2_13_104_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-018-1265-7"},{"key":"e_1_2_13_105_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-003-0494-4"},{"issue":"4","key":"e_1_2_13_106_1","first-page":"927","article-title":"Pharmacokinetics, immunogenicity and safety of bivatuzumab mertansine, a novel CD44v6\u2010targeting immunoconjugate, in patients with squamous cell carcinoma of the head and neck","volume":"30","author":"Sauter A","year":"2007","journal-title":"Int J Oncol"},{"key":"e_1_2_13_107_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2007.10.009"},{"key":"e_1_2_13_108_1","volume-title":"Immune Checkpoints in the Tumor Microenvironment. Seminars in Cancer Biology","author":"Toor SM","year":"2019"},{"key":"e_1_2_13_109_1","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201646875"},{"key":"e_1_2_13_110_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-0527"},{"key":"e_1_2_13_111_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14955"},{"key":"e_1_2_13_112_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.13228"},{"key":"e_1_2_13_113_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003466"},{"key":"e_1_2_13_114_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504030"},{"key":"e_1_2_13_115_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30364-3"},{"key":"e_1_2_13_116_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1602252"},{"key":"e_1_2_13_117_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30421-7"},{"key":"e_1_2_13_118_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30626-6"},{"key":"e_1_2_13_119_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2018.04.008"},{"key":"e_1_2_13_120_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm7010010"},{"key":"e_1_2_13_121_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djx226"},{"key":"e_1_2_13_122_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0277"},{"key":"e_1_2_13_123_1","article-title":"Multicentre retrospective study of nivolumab for recurrent\/metastatic oral squamous cell carcinoma","author":"Yamakawa N","year":"2022","journal-title":"Oral Dis"},{"key":"e_1_2_13_124_1","article-title":"The impact of combined PD\u2010L1 positive score on clinical response to nivolumab in patients with advanced esophageal squamous cell carcinoma","volume":"1","author":"Matsubara Y","year":"2023","journal-title":"Esophagus"},{"key":"e_1_2_13_125_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-018-0131-9"},{"key":"e_1_2_13_126_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2016.5118"},{"key":"e_1_2_13_127_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31999-8"},{"key":"e_1_2_13_128_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.5441"},{"key":"e_1_2_13_129_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32591-7"},{"key":"e_1_2_13_130_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.68.1478"},{"key":"e_1_2_13_131_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30066-3"},{"key":"e_1_2_13_132_1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.13480"},{"key":"e_1_2_13_133_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-021-01807-6"},{"key":"e_1_2_13_134_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100341"},{"key":"e_1_2_13_135_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.07.008"},{"key":"e_1_2_13_136_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003026"},{"key":"e_1_2_13_137_1","article-title":"Safety and efficacy of pembrolizumab in combination with acalabrutinib in advanced head and neck squamous cell carcinoma: phase 2 proof\u2010of\u2010concept study","volume":"28","author":"Taylor MH","year":"2021","journal-title":"Clin Cancer Res"},{"key":"e_1_2_13_138_1","article-title":"Intralesional SD\u2010101 in combination with pembrolizumab in anti\u2010PD\u20101 treatment naive head and neck squamous cell carcinoma: results from a multicenter, phase 2 trial","volume":"28","author":"Cohen EE","year":"2021","journal-title":"Clin Cancer Res"},{"key":"e_1_2_13_139_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-3025"},{"key":"e_1_2_13_140_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.10.006"},{"key":"e_1_2_13_141_1","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-14-0191"},{"key":"e_1_2_13_142_1","volume-title":"PD\u2010L1 Blockade for Cancer Treatment: MEDI4736. Seminars in Oncology","author":"Ibrahim R","year":"2015"},{"key":"e_1_2_13_143_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2018.11.015"},{"key":"e_1_2_13_144_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2018.12.029"},{"issue":"5","key":"e_1_2_13_145_1","first-page":"1307","article-title":"A randomized, open\u2010label, multicenter, global phase 2 study of durvalumab (D), tremelimumab (T), or D plus T, in patients with PD\u2010L1 low\/negative recurrent or metastatic head and neck squamous cell carcinoma: CONDOR. International Journal of Radiation Oncology","volume":"100","author":"Siu L","year":"2018","journal-title":"Biol Phys"},{"key":"e_1_2_13_146_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100385"},{"key":"e_1_2_13_147_1","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2021.1898104"},{"key":"e_1_2_13_148_1","doi-asserted-by":"publisher","DOI":"10.1038\/cr.2016.102"},{"key":"e_1_2_13_149_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2019.08.007"},{"key":"e_1_2_13_150_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002998"},{"key":"e_1_2_13_151_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-16-0665"},{"key":"e_1_2_13_152_1","doi-asserted-by":"publisher","DOI":"10.1097\/COC.0000000000000088"},{"key":"e_1_2_13_153_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz394.071"},{"key":"e_1_2_13_154_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1805131"},{"key":"e_1_2_13_155_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002757"},{"key":"e_1_2_13_156_1","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13810"},{"key":"e_1_2_13_157_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.20569"},{"key":"e_1_2_13_158_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15020495"},{"key":"e_1_2_13_159_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ad.2021.04.011"},{"key":"e_1_2_13_160_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2209813"},{"key":"e_1_2_13_161_1","doi-asserted-by":"publisher","DOI":"10.1016\/bs.acr.2019.03.001"},{"key":"e_1_2_13_162_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.71.7629"},{"key":"e_1_2_13_163_1","doi-asserted-by":"publisher","DOI":"10.1159\/000485562"},{"key":"e_1_2_13_164_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.2955"},{"key":"e_1_2_13_165_1","doi-asserted-by":"publisher","DOI":"10.1186\/2051-1426-3-S2-P150"},{"key":"e_1_2_13_166_1","unstructured":"SiuL EvenC MesiaR et al.A randomized open\u2010label multicenter global phase 2 study of durvalumab (D) tremelimumab (T) or D plus T in patients with PD\u2010L1 low\/negative recurrent or metastatic head and neck squamous cell carcinoma: CONDOR.20181307 p."},{"key":"e_1_2_13_167_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI123955"},{"key":"e_1_2_13_168_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0182-8"},{"key":"e_1_2_13_169_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2018.10.014"},{"key":"e_1_2_13_170_1","first-page":"58","article-title":"Phase II study of monalizumab, a first\u2010in\u2010class NKG2A monoclonal antibody, in combination with cetuximab in previously treated recurrent or metastatic squamous cell carcinoma of the head and neck (R\/M SCCHN): Preliminary assessment of safety and efficacy","volume":"18","author":"Cohen RB","year":"2018","journal-title":"Surgery"},{"key":"e_1_2_13_171_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nucmedbio.2010.06.014"},{"key":"e_1_2_13_172_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12070-020-01877-y"},{"key":"e_1_2_13_173_1","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.9862"},{"key":"e_1_2_13_174_1","doi-asserted-by":"publisher","DOI":"10.1002\/hed.26070"},{"key":"e_1_2_13_175_1","article-title":"Safety and efficacy of cetuximab\u2010containing chemotherapy after immune checkpoint inhibitors for patients with squamous cell carcinoma of the head and neck: a single\u2010center retrospective study","volume":"32","author":"Kurosaki T","year":"2020","journal-title":"Anti\u2010Cancer Drugs"},{"key":"e_1_2_13_176_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.34.1735"},{"key":"e_1_2_13_177_1","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.1.1.7509"},{"key":"e_1_2_13_178_1","doi-asserted-by":"publisher","DOI":"10.5114\/aoms.2013.39234"},{"key":"e_1_2_13_179_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-3944"},{"key":"e_1_2_13_180_1","unstructured":"FDA.FDA approves nivolumab for esophageal squamous cell carcinoma.https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-approves-nivolumab-esophageal-squamous-cell-carcinoma. Accessed June 11 2020"},{"key":"e_1_2_13_181_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.3776"},{"key":"e_1_2_13_182_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0215(19961115)68:4<520::AID-IJC19>3.0.CO;2-8"},{"key":"e_1_2_13_183_1","doi-asserted-by":"publisher","DOI":"10.1002\/hed.1078"},{"key":"e_1_2_13_184_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0022215108003186"},{"key":"e_1_2_13_185_1","article-title":"Radioimmunotherapy in experimental head and neck squamous cell carcinoma: tumour\u2010targeting in vitro and in vivo","volume":"122","author":"Cheng J.","year":"2005","journal-title":"BR J Cancer"},{"key":"e_1_2_13_186_1","unstructured":"FDA.FDA approves new dosing regimen for cetuximab.https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-new-dosing-regimen-cetuximab. Accessed April 07 2021"},{"key":"e_1_2_13_187_1","unstructured":"FDA.FDA approves pembrolizumab for first\u2010line treatment of head and neck squamous cell carcinoma.https:\/\/www.fda.gov\/drugs\/resources\u2010information\u2010approved\u2010drugs\/fda\u2010approves\u2010pembrolizumab\u2010first\u2010line\u2010treatment\u2010head\u2010and\u2010neck\u2010squamous\u2010cell\u2010carcinoma. Accessed June 11 2019"},{"key":"e_1_2_13_188_1","unstructured":"FDA.FDA approves pembrolizumab for cutaneous squamous cell carcinoma.https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-approves-pembrolizumab-cutaneous-squamous-cell-carcinomaAccessed June 24 2020"},{"key":"e_1_2_13_189_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501824"},{"key":"e_1_2_13_190_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801005"},{"key":"e_1_2_13_191_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606774"},{"key":"e_1_2_13_192_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1810865"},{"key":"e_1_2_13_193_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01281-7"},{"key":"e_1_2_13_194_1","unstructured":"FDA.FDA approves nivolumab plus ipilimumab for first\u2010line mNSCLC (PD\u2010L1 tumor expression \u22651%).https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-nivolumab-plus-ipilimumab-first-line-mnsclc-pd-l1-tumor-expression-1. Accessed May 15 2020"},{"key":"e_1_2_13_195_1","unstructured":"FDA.FDA approves pembrolizumab in combination with chemotherapy for first\u2010line treatment of metastatic squamous NSCLC.https:\/\/www.fda.gov\/drugs\/fda-approves-pembrolizumab-combination-chemotherapy-first-line-treatment-metastatic-squamous-nsclc. Accessed December 14 2018"},{"key":"e_1_2_13_196_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70303-5"},{"key":"e_1_2_13_197_1","doi-asserted-by":"publisher","DOI":"10.25251\/skin.2.supp.78"},{"key":"e_1_2_13_198_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30728-4"},{"key":"e_1_2_13_199_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000775"},{"key":"e_1_2_13_200_1","first-page":"1","article-title":"Primary cemiplimab treatment for orbital squamous cell carcinoma is effective and may alleviate the need for orbital exenteration","author":"Tiosano A","year":"2023","journal-title":"Eye"},{"key":"e_1_2_13_201_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.686308"},{"key":"e_1_2_13_202_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-021-09033-7"},{"key":"e_1_2_13_203_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2022.106219"},{"key":"e_1_2_13_204_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-022-02228-3"},{"key":"e_1_2_13_205_1","doi-asserted-by":"publisher","DOI":"10.1002\/hed.26835"},{"key":"e_1_2_13_206_1","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.15395"},{"key":"e_1_2_13_207_1","volume-title":"EAGLE: A Phase 3, Randomized, Open\u2010Label Study of Durvalumab (D) with or without Tremelimumab (T) in Patients (pts) with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R\/M HNSCC)","author":"Licitra LF","year":"2019"},{"key":"e_1_2_13_208_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.08.1085"},{"key":"e_1_2_13_209_1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.12894"},{"key":"e_1_2_13_210_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-015-1406-8"},{"key":"e_1_2_13_211_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30181-X"},{"key":"e_1_2_13_212_1","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.15996"},{"key":"e_1_2_13_213_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anl.2022.02.006"},{"key":"e_1_2_13_214_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34463"},{"key":"e_1_2_13_215_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10388-021-00850-0"},{"key":"e_1_2_13_216_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0041-1733317"},{"key":"e_1_2_13_217_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00290"},{"key":"e_1_2_13_218_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-2635"},{"key":"e_1_2_13_219_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2016-0496"},{"key":"e_1_2_13_220_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-2214"},{"key":"e_1_2_13_221_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djaa063"}],"container-title":["Cancer Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cnr2.1802","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T15:29:55Z","timestamp":1692631795000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cnr2.1802"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,12]]},"references-count":220,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["10.1002\/cnr2.1802"],"URL":"https:\/\/doi.org\/10.1002\/cnr2.1802","archive":["Portico"],"relation":{},"ISSN":["2573-8348","2573-8348"],"issn-type":[{"value":"2573-8348","type":"print"},{"value":"2573-8348","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,12]]},"assertion":[{"value":"2022-02-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-24","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-12","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e1802"}}